Skip to content

OptimizeRx OPRX Debt Maturity - 2024

Debt Maturity - 2024 at other companies

Claritev Corporation logo
Claritev CorporationCTEV

Other financials

Income statement

See full
Revenue$19.8M-9.5%
Gross profit$14.9M+11.9%
Operating income$396.0K+119%
Net income-$495.0K+77.5%
EPS (diluted)-$0.03+75.0%

Balance sheet

See full
Cash & equivalents$20.2M+21.7%
Total debt$23.7M-27.7%
Total equity$129.6M+11.5%
Total assets$167.3M-0.3%

Cash flow

See full
Operating cash flow-$467.0K-112%
CapEx$21.0K-22.2%
Free cash flow-$488.0K-113%

Valuation

See full
Market cap$107.34M-54.1%
Enterprise value$110.88M-55.0%
P/E15.7×
P/S-1.2×

Profitability

See full
Gross margin70%+14.1pp
Operating margin13.2%
Net margin6.4%+3.6pp
FCF margin13.4%+4.8pp

Returns & leverage

See full
Return on equity5.6%+3.3pp
Debt / equity0.2×-0.1×
Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's debt maturity - 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OptimizeRx's debt maturity - 2024?
OptimizeRx (OPRX) reported debt maturity - 2024 of $1.5M in Q1 2026.
How has OptimizeRx's debt maturity - 2024 changed year-over-year?
OptimizeRx's debt maturity - 2024 decreased by 0.0% year-over-year, from $1.5M to $1.5M.